WASHINGTON (dpa-AFX) - Abbott (ABT) and the Drugs for Neglected Diseases initiative or DNDi reached a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Through this collaboration, DNDi and Abbott scientists would focus initial efforts on discovering and advancing novel antimicrobial agents with activity against these neglected diseases. Abbott said this new deal expands this relationship, and provides DNDi access to selected classes of molecules and accompanying data generated by Abbott that are crucial for the development of effective and accessible new treatments for neglected diseases. The deal implies both DNDi and Abbott share their unique scientific expertise and resources, DNDi gains access to Abbott compounds, data and information to accelerate drug development, non-exclusive licensing structure for relevant IP in the neglected diseases field provides flexibility and any resulting products would be provided in endemic countries at the lowest sustainable price to expand patient access.
Copyright RTT News/dpa-AFX
